Sona Nanotech Closes Private Placement Financing to Raise $750,000 in Gross Proceeds and Announces Additional Financing

Sona Nanotech Closes Private Placement Financing to Raise $750,000 in Gross Proceeds and Announces Additional Financing

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has closed its private placement that was announced on October 18, 2023 with the issuance of 3,750,000 shares at $0.20 per share and 1,875,000 common share purchase warrants exercisable to purchase an additional common share of Sona at a price of $0.30 per share until November 24, 2025. (the "Financing"). Insiders subscribed for 175,000 common shares and 87,500 common share purchase warrants. As previously disclosed, Sona intends to use the net proceeds of the Financing for further research and development of its Targeted Hyperthermia TherapyTM ("THT"), as well as for general working capital purposes.

Numus Capital Corp. (the "Agent"), a registered Exempt Market Dealer, acted as exclusive agent for the Financing. In connection with the private placement, Sona paid the Agent cash commissions of $53,650 and 268,125 non-transferable share purchase warrants (the "Broker Warrants"). Each Broker Warrant entitles the holder to acquire one Share at an exercise price of $0.30 until November 24, 2025. The Agent is a related party to Sona, a director of Sona being indirectly a principal shareholder of the Agent, as well such director of Sona also being a director and officer of the Agent.

All securities issued pursuant to the Financing will be subject to a hold period until March 25, 2024.

Sona is also pleased to announce that it plans to raise an additional $60,000 through a non-brokered private placement (the "Additional Financing") of up to 300,000 units of Sona (each, a "Unit") at $0.20 per Unit (the "Offering Price"). Each Unit will consist of one common share of Sona and one-half (1/2) of a common share purchase warrant (each whole warrant, a "Warrant"). Each whole Warrant will be exercisable to purchase one additional common share of Sona at a price of $0.30 per share for a period of 24 months from the closing date of the Additional Financing (the "Closing Date"), which is expected to occur on December 1, 2023.

The Agent will also act as the exclusive agent for the Additional Financing. As compensation for its services, the Agent will receive cash compensation equal to 7.5% of the gross proceeds of the Additional Financing. The Agent will also receive non-transferable common share purchase warrants (the "Broker Warrants") which will entitle the Agent to acquire such number of common shares as is equal to 7.5% of the number of Units placed by the Agent. The Broker Warrants will be exercisable at a price of $0.30 per share any time for a period of 24 months from the Closing Date.

Sona also intends to use the net proceeds of the Additional Financing for general working capital purposes.

Completion of the Additional Financing is subject to the satisfaction of certain conditions, and all securities issued pursuant to the Additional Financing will be subject to a hold-period of four months and a day commencing from the Closing Date.

Contact:
David Regan, CEO
+1-902-536-1932
david@sonanano.com

About Sona Nanotech Inc.
Sona Nanotech, a nanotechnology life sciences company, is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors. The heat is delivered to tumors by infrared light that is absorbed by Sona's gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (41-48°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion - thus enabling drugs to reach all tumor compartments more effectively. The size, shape, and surface chemistry of the nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Sona's initial clinical target is colorectal cancer.

Sona has developed multiple proprietary methods for the manufacture of gold nanoparticles which it uses for the development of both cancer therapies and diagnostic testing platforms. Sona Nanotech's gold nanorod particles are cetyltrimethylammonium ("CTAB") free, eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. It is expected that Sona's gold nanotechnologies may be adapted for use in applications, as a safe and effective delivery system for multiple medical treatments, subject to the approval of various regulatory boards, including Health Canada and the FDA.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This press release includes certain "forward-looking statements" under applicable Canadian securities legislation, including statements regarding the anticipated applications of Targeted Hyperthermia Therapy, Sona's preclinical study plans, the potential impact of the planned studies and its product development plans. Forward-looking statements are necessarily based upon a number of assumptions or estimates that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements, including the risk that Sona may not be able to successfully obtain sufficient clinical and other data to submit regulatory submissions, raise sufficient additional capital or develop the envisioned therapy, and the risk that THT may not prove to have the benefits currently anticipated. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Sona disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Not for distribution to United States newswire services or for dissemination in the United States.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/188760

News Provided by Newsfile via QuoteMedia

SONA:CNX
Sona Nanotech

Sona Nanotech Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Sona Nanotech

Sona Nanotech


Keep reading...Show less
Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona's Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that a detailed biomarker analysis of the recently reported pre-clinical melanoma study conducted at Dalhousie University (the "Study") indicates that, beyond shrinking tumors on its own, Sona's Targeted Hyperthermia Therapy ("THT") also stimulates the innate immune system to target and eliminate untreated (contralateral) tumors when combined with a standard immunotherapeutic drug, IL-2. (See figure #1, below.) On the basis of efficacy data achieved in two different murine cancer models (triple negative breast cancer and malignant melanoma), the Company is now proceeding with safety and biocompatibility testing that will be required by regulating agencies to enter into human studies.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer

Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona's THT achieved responses in a preclinical melanoma model equal to that which was recently reported from its triple negative breast cancer study. THT effectively treated melanoma tumors in all animals when administered on its own. Further, when THT was combined with doses of interleukin-2 ("IL-2"), a standard immunotherapy, a synergistic effect was shown whereby greater treatment response, measured by tumor volume reduction, was achieved in comparison to either approach alone.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sona Appoints Chief Medical Officer and Files Provisional Conjugation Patent

Sona Appoints Chief Medical Officer and Files Provisional Conjugation Patent

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to advise that it has appointed Dr. Carman Giacomantonio MD, MSc., FRCSC (Cav.) to be the Company's Chief Medical Officer. Dr. Giacomantonio is a practicing Surgical Oncologist at the QEII Health Sciences Centre and a Professor of Surgery at Dalhousie University. Dr. Giacomantonio leads a productive translational research group at Dalhousie University and has successfully initiated two clinical trials in cancer immunotherapy. He is widely published in the field of cancer immunobiology and immunotherapy research, and a recognized innovator in the field of intra-tumoral cancer immunotherapy. Dr. Giacomantonio currently serves on Sona's Advisory Board and is the Principal Investigator for Sona's pre-clinical studies using Sona's gold nanorods in its Targeted Hyperthermia Therapy ("THT") for triple negative breast cancer, melanoma, and colorectal cancer. Sona is extremely excited to have Dr. Giacomantonio's vision and experience to lead the development of our THT-based immunotherapy towards first-in-human clinical trials.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sona's Cancer Therapy Creates a Systemic Immune Response in Murine Breast Cancer Model

Sona's Cancer Therapy Creates a Systemic Immune Response in Murine Breast Cancer Model

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces further results from the triple negative breast cancer murine model portion of its current research study at Dalhousie University (the "Study") which confirms that the previously reported tumor volume reduction was due to activation of a tumor specific systemic immune response. These data relate to the follow-up biomarker analysis performed on the previously reported cohort of animals that showed a statistically significant synergistic effect in the shrinking of both treated and untreated tumors in animals bearing multiple tumors after treatment with the combination of Sona's targeted hyperthermia therapy ("THT") and interleukin-2 ("IL-2"), an immunotherapy agent widely used to treat human cancer patients.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study

Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce further positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). The Company was provided with data from the Study that indicates the response in a pre-clinical triple negative breast cancer model treated with the combination of Sona's targeted hyperthermia therapy ("THT") and interleukin-2 ("IL-2"), a standard immunotherapy, is statistically significantly superior to results observed from treatment with either agent individually or the control group. This second phase of the Study has documented that, in a cohort of six animals, 66 of treated triple negative breast cancer, the most aggressive and therapy resistant form, mouse tumors bearing gold nanorods and IL-2 responded to the combination therapy, resulting in a flattening of the tumor growth curves, as shown in the below graph. The generation of hyperthermia involved exposing tumors previously injected intratumorally with Sona's gold nanorods and IL-2 to a single dose of near infrared light.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Carbon Done Right Announces Receipt of Fifth Disbursement of Financing for Sierra Leone Rewilding Project

Carbon Done Right Announces Receipt of Fifth Disbursement of Financing for Sierra Leone Rewilding Project

Carbon Done Right Developments Inc. (TSXV: KLX) (FSE: Q1C) ("Carbon Done Right" or the "Company") a leading provider of high-quality carbon credits sourced exclusively from afforestation and reforestation projects developed and owned by the Company and its stakeholders, is pleased to announce the completion of all milestones required for the fifth disbursement under the pre-purchase agreement announced on the 14th June, 2023.

Carbon Done Right CEO James Tansey stated, "This fifth milestone demonstrates our continued progress with the project's implementation. Our team is actively planting through the summer and has already cleared over 500 ha of land. The restoration sites focus on abandoned land in Sierra Leone and provide direct income to the smallholders within these communities and long-term revenue sharing benefits. Restoring nature's capacity to sequester carbon is a key strategy for reversing and preventing climate change. The in-country team is busy preparing for the 2024 planting season where we expect to plant native tree species on up to 2,000 ha of additional degraded land."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Forward Water Technologies Corp. and Fraser Mackenzie Accelerator Corp Announce Revisions to Terms of Proposed Transaction and Concurrent Financing, Signing of Definitive Agreement for Proposed Business Combination

Forward Water Technologies Corp. and Fraser Mackenzie Accelerator Corp Announce Revisions to Terms of Proposed Transaction and Concurrent Financing, Signing of Definitive Agreement for Proposed Business Combination

Forward Water Technologies Corp. (TSXV: FWTC) (" FWTC ") and Fraser Mackenzie Accelerator Corp. (TSXV: FMAC.P) (the " FMAC ") are pleased to announce that, further to their joint news releases of May 14, 2024 announcing the proposed transaction between FWTC and FMAC (the "Transaction"), and June 18, 2024 announcing the proposed private placement financing concurrent with the Transaction (the "Concurrent Financing"), they have revised the terms of the Transaction and the Concurrent Financing and have entered into a definitive agreement dated July 22, 2024 with respect to the Transaction (the "Definitive Agreement"). The Transaction is intended to be FMAC's qualifying transaction for purposes of TSX Venture Exchange ("TSXV") policies. FWTC, after completion of the Transaction, is referred to as the " Resulting Issuer ".

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bitcoin Well Announces Bill Payments Via the Lightning Network and Unique User Signup Milestone

Bitcoin Well Announces Bill Payments Via the Lightning Network and Unique User Signup Milestone

(TheNewswire)

Bitcoin Well Inc.

Edmonton, Alberta July 16, 2024 TheNewswire Bitcoin Well Inc. (" Bitcoin Well " or the " Company ") ( TSXV: BTCW; OTCQB: BCNWF ), the non-custodial bitcoin business on a mission to enable independence announces the ability for customers in Canada to pay their household bills and credit cards with bitcoin on the Lightning Network, as well as the achievement of 21,000 unique users signed up to the Bitcoin Portal.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
RecycLiCo Battery Materials Inc. Granted European Unitary Patent for Innovative Lithium-Ion Battery Recycling Process

RecycLiCo Battery Materials Inc. Granted European Unitary Patent for Innovative Lithium-Ion Battery Recycling Process

-

RecycLiCo Battery Materials Inc. ("RecycLiCo" or the "Company"), TSX.V: AMY, OTCQB: AMYZF, FSE: ID4, a leader in sustainable lithium-ion battery recycling technology, is pleased to announce the registration of the European Unitary Patent (Patent Application No. 17870326.0) for its pioneering hydrometallurgical recycling solution. This patent grant solidifies the Company's intellectual property portfolio in Europe, a key market focused on electrification and sustainable battery technologies.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Forward Water Technologies Corp. Business Update: New Projects Initiated with Major Corporations in the Food and Beverage Sector

Forward Water Technologies Corp. Business Update: New Projects Initiated with Major Corporations in the Food and Beverage Sector

Forward Water Technologies Corp. ("FWTC") (TSXV:FWTC) has initiated new projects via direct customer contact in the food and beverage space to enable more efficient wastewater handling in the production of food and beverage products with globally positioned multinational manufacturers. FWTC has entered early planning stages for pilot or early commercial trials after being selected for evaluation by two unique clients. Projects, if successful, would represent a significant reduction in water usage for the manufacturing of products and simultaneously reduce the energy footprint currently required. This energy reduction would not only lead to cost savings but also have a major impact in reducing CO2 emissions

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Bitcoin Well Announces 87% Quarterly Growth in Q2 on the Bitcoin Portal

Bitcoin Well Announces 87% Quarterly Growth in Q2 on the Bitcoin Portal

(TheNewswire)

Bitcoin Well Inc.

Edmonton, Alberta TheNewswire - July 10, 2024 Bitcoin Well Inc. (" Bitcoin Well " or the " Company ") ( TSXV: BTCW ) ; ( OTCQB: BCNWF ), the non-custodial bitcoin business on a mission to enable independence, today announces that Bitcoin Portal volumes have grown by over 87% in Q2 2024 (CAD ~$16.85 million) compared to Q1 2024 (CAD ~$9 million) . With Bitcoin Portal volumes in the USA growing by over 260% in Q2 (CAD ~$0.4 million) compared to Q1 2024 (CAD ~$0.11 million) .

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Sona Nanotech

Sona Nanotech Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Latest Press Releases

Related News

×